GlassScriptPhysician profile
Caesar Castro Agagan
NPI 1285610576
$11,356.00
in general payments reported to CMS, 2019-2025
39 companies · $2,555 in 2025
The $2,555 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,880 · 2020: $801 · 2021: $1,276 · 2022: $1,357 · 2023: $1,717 · 2024: $1,769 · 2025: $2,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,041.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,486.00 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,610.49 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,309.59 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $673.22 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $521.06 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Electromed, INC. | $434.70 | 2019-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $416.42 | 2019-2024 | Opsumit |
| Insmed, INC. | $406.43 | 2019-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $338.98 | 2020-2025 | Cuvitru, Glassia, Hyqvia |
| Genentech USA, INC. | $329.54 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $314.18 | 2019-2025 | |
| Genzyme Corporation | $266.97 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $231.70 | 2019-2020 | |
| Mylan Specialty L.P. | $222.91 | 2019-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $208.59 | 2020-2024 | Acthar |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $189.29 | 2020-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $153.77 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Pulmonx Corporation | $133.77 | 2022-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Amgen INC. | $123.86 | 2021-2024 | Tezspire |
| Vifor Pharma, INC. | $122.27 | 2024-2025 | Zemaira |
| Galderma Laboratories, L.P. | $113.71 | 2025 | Nemluvio |
| Gilead Sciences, INC. | $106.36 | 2021-2022 | |
| Philips North America LLC | $87.35 | 2019-2024 | (Ak6) Vest Therapy |
| Janssen Pharmaceuticals, INC | $65.88 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $62.51 | 2022-2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $61.35 | 2025 | Ohtuvayre |
| Alexion Pharmaceuticals, INC. | $54.26 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $42.16 | 2019 | |
| Baxter Healthcare | $38.57 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Bayer Healthcare Pharmaceuticals INC. | $36.59 | 2021-2022 | |
| Shire North American Group INC | $29.58 | 2019 | |
| Optinose US, INC. | $26.65 | 2019-2021 | |
| Abbvie INC. | $25.08 | 2024 | |
| Csl Behring | $24.46 | 2020 | |
| Viatris Specialty LLC | $18.81 | 2025 | Yupelri |
| Inogen, INC. | $18.32 | 2022-2024 | |
| Pfizer INC. | $18.18 | 2024 | |
| La Jolla Pharmaceutical Company | $16.71 | 2020 | |
| Advanced Respiratory, INC | $15.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caesar Agagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.